More than six million Americans are living with Alzheimer’s disease – it slowly steals your memories and takes away your mind ...

The panel of Food and Drug Administration experts voted 17-1 that drugmaker Brainstorm’s stem cell-based treatment has not ...

An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem ...

Alzheimer’s drug Leqembi has full FDA approval THE ASSOCIATED PRESS July 7, 2023 at 07:30 JST Share Tweet list Print This image provided by Eisai in January 2023 shows vials and packaging for ...

The US FDA has issued proposal guidance to assist companies developing new treatments for patients in the early stages of Alzheimer’s disease, before the onset of noticeable (overt) dementia.

Commissions we earn from partner links on this page do not affect our opinions or evaluations. Our editorial content is based on thorough research and guidance from the Forbes Health Advisory Board.

The FDA also gave full approval to a drug called Leqembi, which slowed Alzheimer’s patients’ functional and cognitive decline by 27% over 18 months, according to trial data.

Lecanemab, better known as Leqembi, is the first traditionally approved treatment to address the underlying biology of ...

A medication that could help treat early stages of Alzheimer's disease is on track to be approved for manufacturing and sales in Japan after being endorsed by a health ministry expert panel on ...

We’ll send you a myFT Daily Digest email rounding up the latest Vivek Ramaswamy news every morning. US biotech company Roivant Sciences has moved to distance itself from its founder, Vivek ...

For decades, attempts to treat or slow Alzheimer's disease (AD) — a brain disorder that causes dementia through damage to brain cells and other changes in the brain — have been dispiriting ...

More than 6,000,000 Americans are living with Alzheimer's disease – it slowly steals your memories and takes away your mind ...